HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF-β bifunctional antibody fusion protein, in combination with...
Hence then, the article about akeso announces first patient dosed in registrational phase ii study of tigit tgf b bifunctional antibody fusion protein ak130 combined with ivonescimab for advanced pancreatic cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer )
Also on site :
- Five killed in helicopter crash on Africa’s highest mountain (VIDEO)
- transcosmos and V, Inc. launch metaverse creator services for VRChat via Geek Jack, transcosmos's cross-border e-commerce site for entertainment items
- The Christmas Day Storm